Sun Pharma Freezes Generic Eloxatin Sales
Sun Pharmaceutical Industries Inc. has agreed to temporarily halt its sales of oxaliplatin, the active ingredient in Sanofi-Aventis US LLC's colon cancer drug Eloxatin, as the parties decide how to proceed...To view the full article, register now.
Already a subscriber? Click here to view full article